Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Research & Development (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Research & Development data on record, last reported at $31.8 million in Q4 2025.

  • For Q4 2025, Research & Development rose 17.47% year-over-year to $31.8 million; the TTM value through Dec 2025 reached $111.6 million, changed N/A, while the annual FY2025 figure was $101.6 million, 10.83% down from the prior year.
  • Research & Development reached $31.8 million in Q4 2025 per CAI's latest filing, up from $25.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.8 million in Q4 2025 and bottomed at $25.0 million in Q2 2025.